

Keytruda® (pembrolizumab) – Expanded indication

- On March 21, 2022, Merck announced the FDA approval of Keytruda (pembrolizumab), as a single agent, for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
 - Keytruda is also approved in combination with <u>Lenvima® (lenvatinib</u>), for the treatment of patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
- In addition to endometrial carcinoma, Keytruda is approved for melanoma, non-small cell lung cancer, head and neck squamous cell cancer, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial cancer, MSI-H or dMMR cancer, MSI-H or dMMR colorectal cancer, gastric cancer, esophageal cancer, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, renal cell carcinoma, tumor mutational burden-high cancer, cutaneous squamous cell carcinoma, and triple-negative breast cancer.
- The approval of Keytruda for the expanded indication was based on KEYNOTE-158, a non-randomized, open-label, multi-cohort study. The study included 90 patients with unresectable or metastatic MSI-H or dMMR endometrial carcinoma who received at least one dose of Keytruda. The major efficacy outcome measures were objective response rate (ORR) and duration of response (DOR).
 - The ORR was 46% (95% CI: 35, 56).
 - The median DOR was not reached (range: 2.9, 55.7+).
- The recommended dose of Keytruda for the treatment of MSI-H or dMMR endometrial carcinoma is 200 mg intravenously every 3 weeks or 400 mg every 6 weeks. Keytruda should be administered until disease progression, unacceptable toxicity, or up to 24 months.
 - Refer to the Keytruda drug label for dosing for all its other indications.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.